|
Name |
Calbistrin G
|
| Molecular Formula | C28H44O8 | |
| IUPAC Name* |
[(1S,3R,4aR,7S,8S,8aS)-8-(2,3-dihydroxypropanoyl)-3,7,8-trimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyldeca-4,6-dienoate
|
|
| SMILES |
C[C@@H]1C[C@@H]2C=C[C@@H]([C@]([C@H]2[C@H](C1)OC(=O)[C@@H](C)[C@H](/C(=C/C=C/[C@@H]([C@@H](C)O)O)/C)O)(C)C(=O)C(CO)O)C
|
|
| InChI |
InChI=1S/C28H44O8/c1-15-12-20-11-10-17(3)28(6,26(34)22(32)14-29)24(20)23(13-15)36-27(35)18(4)25(33)16(2)8-7-9-21(31)19(5)30/h7-11,15,17-25,29-33H,12-14H2,1-6H3/b9-7+,16-8+/t15-,17+,18+,19-,20+,21+,22?,23+,24-,25+,28+/m1/s1
|
|
| InChIKey |
ASHQRLOFJNKMPY-NKJZOWFESA-N
|
|
| Synonyms |
Calbistrin G; CHEMBL3358713; [(1S,3R,4aR,7S,8S,8aS)-8-(2,3-dihydroxypropanoyl)-3,7,8-trimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyl-deca-4,6-dienoate
|
|
| CAS | NA | |
| PubChem CID | 118723027 | |
| ChEMBL ID | CHEMBL3358713 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 508.6 | ALogp: | 2.5 |
| HBD: | 5 | HBA: | 8 |
| Rotatable Bonds: | 11 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 145.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 36 | QED Weighted: | 0.172 |
| Caco-2 Permeability: | -5.145 | MDCK Permeability: | 0.00023443 |
| Pgp-inhibitor: | 0.089 | Pgp-substrate: | 0.998 |
| Human Intestinal Absorption (HIA): | 0.066 | 20% Bioavailability (F20%): | 0.021 |
| 30% Bioavailability (F30%): | 0.925 |
| Blood-Brain-Barrier Penetration (BBB): | 0.132 | Plasma Protein Binding (PPB): | 53.47% |
| Volume Distribution (VD): | 0.423 | Fu: | 15.60% |
| CYP1A2-inhibitor: | 0.055 | CYP1A2-substrate: | 0.109 |
| CYP2C19-inhibitor: | 0.015 | CYP2C19-substrate: | 0.753 |
| CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.27 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.082 |
| CYP3A4-inhibitor: | 0.613 | CYP3A4-substrate: | 0.275 |
| Clearance (CL): | 3.333 | Half-life (T1/2): | 0.738 |
| hERG Blockers: | 0.084 | Human Hepatotoxicity (H-HT): | 0.804 |
| Drug-inuced Liver Injury (DILI): | 0.854 | AMES Toxicity: | 0.021 |
| Rat Oral Acute Toxicity: | 0.415 | Maximum Recommended Daily Dose: | 0.017 |
| Skin Sensitization: | 0.116 | Carcinogencity: | 0.077 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
| Respiratory Toxicity: | 0.884 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003294 | ![]() |
0.856 | D02RQU | ![]() |
0.257 | ||
| ENC003292 | ![]() |
0.825 | D0E9KA | ![]() |
0.229 | ||
| ENC004660 | ![]() |
0.338 | D06WTZ | ![]() |
0.215 | ||
| ENC003895 | ![]() |
0.328 | D0X7XG | ![]() |
0.198 | ||
| ENC003665 | ![]() |
0.321 | D06PTA | ![]() |
0.191 | ||
| ENC004127 | ![]() |
0.319 | D0S0AS | ![]() |
0.191 | ||
| ENC004128 | ![]() |
0.310 | D0F7NQ | ![]() |
0.191 | ||
| ENC003132 | ![]() |
0.291 | D0G7KJ | ![]() |
0.190 | ||
| ENC003119 | ![]() |
0.286 | D03IKT | ![]() |
0.189 | ||
| ENC003817 | ![]() |
0.277 | D0H0ND | ![]() |
0.188 | ||